The role of IL-6 in the radiation response of prostate cancer

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Wu, Chun Te ^a,b   Chen, Miao Fen ^a,b   Chen, Wen Cheng ^a,b   Hsieh, Ching Chuan ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

IL 6; Irradiation; Prostate cancer

Indexed keywords

INTERLEUKIN 6; PROTEIN P53; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DAMAGE; IN VITRO STUDY; IN VIVO STUDY; IRRADIATION; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; RADIATION RESPONSE; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; TUMOR GROWTH;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROSTATIC NEOPLASMS; RADIATION TOLERANCE;

EID: 84880697448     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-159     Document Type: Article

References (40)

1. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004, 10:33-39. 10.1038/nm972, 14702632.
2. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008, 118:3051-3064. 2518074, 18725989.
3. Bernier J, Hall EJ, Giaccia A. Radiation oncology: a century of achievements. Nat Rev Cancer 2004, 4(9):737-747.
4. Rodemann HP, Blaese MA. Responses of normal cells to ionizing radiation. Semin Radiat Oncol 2007, 17(2):81-88. 10.1016/j.semradonc.2006.11.005, 17395038.
5. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010, 140(6):883-899. 10.1016/j.cell.2010.01.025, 2866629, 20303878.
6. Deorukhkar A, Krishnan S. Targeting inflammatory pathways for tumor radiosensitization. Biochem Pharmacol 2010, 80(12):1904-1914. 10.1016/j.bcp.2010.06.039, 3090731, 20599771.
7. Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 2005, 23:1-21. 10.1146/annurev.immunol.23.021704.115806, 15771564.
8. Malinowska K, Neuwirt H, Cavarretta IT, et al. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer 2009, 16:155-169.
9. Bonner JA, Trummell HQ, Willey CD, Plants BA, Raisch KP. Inhibition of STAT-3 results in radiosensitization of human squamous cell carcinoma. Radiother Oncol 2009, 92(3):339-344. 10.1016/j.radonc.2009.06.022, 19616333.
10. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 2007, 110(9):1911-1928. 10.1002/cncr.22999, 17849470.
11. Schafer ZT, Brugge JS. IL-6 involvement in epithelial cancers. J Clin Invest 2007, 117(12):3660-3663. 10.1172/JCI34237, 2096452, 18060028.
12. Culig Z, Puhr M. Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol 2012, 360(1-2):52-58. 3409376, 21664423.
13. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012, 38(7):904-910. 10.1016/j.ctrv.2012.04.007, 22651903.
14. Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1994, 73(7):1882-1888. 10.1002/1097-0142(19940401)73:7<1882::AID-CNCR2820730718>3.0.CO;2-R, 8137215.
15. Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 1999, 19(2B):1427-1432.
16. Chen MF, Chen PT, Lu MS, Lin PY, Chen WC, Lee KD. IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol Cancer 2013, 12(1):26. 10.1186/1476-4598-12-26, 3667147, 23561329.
17. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9(3):162-174. 10.1038/nri2506, 2828349, 19197294.
18. Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res 2010, 70(14):5679-5685. 10.1158/0008-5472.CAN-09-4446, 2918387, 20631066.
19. Wu CT, Hsieh CC, Lin CC, Chen WC, Hong JH, Chen MF. Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells. J Mol Med (Berl) 2012, 90(11):1343-1355.
20. Chen MF, Chen WC, Chang YJ, Wu CF, Wu CT. Role of DNA methyltransferase 1 in hormone-resistant prostate cancer. J Mol Med (Berl) 2010, 88(9):953-962.
21. Wu CT, Chen WC, Liao SK, Hsu CL, Lee KD, Chen MF. The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy. Endocr Relat Cancer 2007, 14(3):633-643. 10.1677/ERC-07-0073, 17914094.
22. Chen MF, Hsieh CC, Chen WC, Lai CH. Role of interleukin-6 in the radiation response of liver tumors. Int J Radiat Oncol Biol Phys 2012, 84(5):e621-e630. 10.1016/j.ijrobp.2012.07.2360, 22975618.
23. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008, 181(8):5791-5802. 2575748, 18832739.
24. Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol 2009, 182(1):240-249.
25. Myhre O, Andersen JM, Aarnes H, Fonnum F. Evaluation of the probes 2',7'-dichlorofluorescin diacetate, luminol, and lucigenin as indicators of reactive species formation. Biochem Pharmacol 2003, 65(10):1575-1582. 10.1016/S0006-2952(03)00083-2, 12754093.
26. Sharma S, Sharma MC, Sarkar C. Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis. Histopathology 2005, 46(5):481-489. 10.1111/j.1365-2559.2005.02142.x, 15842629.
27. Tulard A, Hoffschir F, de Boisferon FH, Luccioni C, Bravard A. Persistent oxidative stress after ionizing radiation is involved in inherited radiosensitivity. Free Radic Biol Med 2003, 35(1):68-77. 10.1016/S0891-5849(03)00243-0, 12826257.
28. Wallner L, Dai J, Escara-Wilke J, et al. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res 2006, 66:3087-3095. 10.1158/0008-5472.CAN-05-3447, 16540658.
29. Fizazi K, De Bono JS, Flechon A, et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer 2012, 48:85-93.
30. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003, 9(13):4653-4665. 2929399, 14581334.
31. Leu CM, Wong FH, Chang C, Huang SF, Hu CP. Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene 2003, 22(49):7809-7818. 10.1038/sj.onc.1207084, 14586407.
32. Lowndes NF, Murguia JR. Sensing and responding to DNA damage. Curr Opin Genet Dev 2000, 10(1):17-25. 10.1016/S0959-437X(99)00050-7, 10679395.
33. Achanta G, Huang P. Role of p53 in sensing oxidative DNA damage in response to reactive oxygen species-generating agents. Cancer Res 2004, 64(17):6233-6239. 10.1158/0008-5472.CAN-04-0494, 15342409.
34. Colombel M, Radvanyi F, Blanche M, et al. Androgen suppressed apoptosis is modified in p53 deficient mice. Oncogene 1999, 10:1269-1274.
35. Burchardt M, Burchardt T, Shabsigh A, et al. Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells. Prostate 2001, 48:225-230. 10.1002/pros.1101, 11536301.
36. Niu G, Wright KL, Ma Y, et al. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol 2005, 25(17):7432-7440. 10.1128/MCB.25.17.7432-7440.2005, 1190305, 16107692.
37. Sun Y, Nelson PS. Molecular pathways: involving microenvironment damage responses in cancer therapy resistance. Clin Cancer Res 2012, 18(15):4019-4025. 10.1158/1078-0432.CCR-11-0768, 22619305.
38. Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 2003, 9(1):370-376.
39. Steiner H, Berger AP, Godoy-Tundidor S, et al. An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6. Eur J Cancer 2004, 40(7):1066-1072. 10.1016/j.ejca.2003.11.033, 15093584.
40. Yang L, DeBusk LM, Fukuda K, et al. Expansion of myeloid immune suppressor Gr + CD11b + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004, 6(4):409-421. 10.1016/j.ccr.2004.08.031, 15488763.